biotech / news / / STAT
Kelonia Therapeutics will be acquired by Eli Lilly.
Eli Lilly is acquiring Kelonia Therapeutics for $3.2 billion with contingent milestones.
KEY POINTS
- Kelonia has survived on just $60 million in funding over five years before the deal.
- Kelonia was within a week of running out of cash three separate times.
- The acquisition could potentially double in value if Kelonia meets certain milestones.
COMPANIES
Summarized by Newsio from STAT. How we summarize →